Update on genetic and clinical aspects of primary hyperparathyroidism

Clinical Endocrinology

Volumn 59, Issue 5, 2003, Pages 539-554

  Miedlich, S ^a   Krohn, K ^a   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCITRIOL; CALCIUM ION; CALCIUM SENSING RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GENE PRODUCT; GESTAGEN; PARATHYROID HORMONE; PHOSPHATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; VITAMIN D RECEPTOR;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; BREAST CANCER; CHROMOSOME ABERRATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOCRINE DISEASE; ENDOCRINE TUMOR; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; GENE; GENE MUTATION; GENOTYPE; HORMONE DEFICIENCY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; IMMUNOASSAY; MAJOR CLINICAL STUDY; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE; PARATHYROID HORMONE RELEASE; PARATHYROID TUMOR; PARATHYROIDECTOMY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VITAMIN D DEFICIENCY;

ADENOMA; AGED; CALCIUM; CHROMOSOME ABERRATIONS; CYCLIN D1; DIPHOSPHONATES; ESTROGENS; FEMALE; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; PROTO-ONCOGENE PROTEINS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0242351683     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.t01-1-01755.x     Document Type: Review

References (189)

1. Adami, S., Mian, M., Bertoldo, F., Rossini, M., Jayawerra, P., O'Riordan, J.L. & Lo, C. (1990) Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clinical Endocrinology, 33, 391-397.
2. Adami, S., Zamberlan, N., Mian, M., Dorizzi, R., Rossini, M., Braga, B., Gatti, D., Bertoldo, F. & Locascio, V. (1994) Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone and Mineral, 25, 75-82.
3. Adams, J.S., Kantorovich, V., Wu, C., Javanbakht, M. & Hollis, B.W. (1999) Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. Journal of Clinical Endocrinology and Metabolism, 84, 2729-2730.
4. Agarwal, S.K., Schrock, E., Kester, M.B., Burns, A.L., Heffess, C.S., Ried, T. & Marx, S.J. (1998) Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genetics and Cytogenetics, 106, 30-36.
5. Albright, F. & Reifenstein, E.C. (1948) Clinical findings in primary hyper-parathyroidism. In: The Parathyroid Glands and Metabolic Bone Disease, pp. 54-72. Baltimore: Williams & Wilkins.
6. Anonymous. (1991) Proceedings of the NIH Consensus Development Conference on diagnosis and management of asymptomatic primary hyperparathyroidism. Bethesda, Maryland, October 29-31, 1990. Journal of Bone and Mineral Research, 6 (Suppl. 2), S1-S166.
7. Anonymous. (1994) NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. Journal of the American Medical Association, 212, 1942-1948.
8. Antonsen, J.E., Sherrard, D.J. & Andress, D.L. (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney International, 53, 223-227.
9. Arnold, A. (1994) Molecular basis of primary hyperparathyroidism. In: The Parathyroids (eds J. P. Bilezikian, M. A. Levine & R. Marcus), pp. 407-421. Raven, New York.
10. Arnold, A., Staunton, C.E., Kim, H.G., Gaz, R.D. & Kronenberg, H.M. (1988) Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. New England Journal of Medicine, 318, 658-662.
11. Arnold, A., Kim, H.G., Gaz, R.D., Eddy, R.L., Fukushima, Y., Byers, M.G., Shows, T.B. & Kronenberg, H.M. (1989) Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. Journal of Clinical Investigation, 83, 2034-2037.
12. Berridge, M.J. (1989) The Albert Lasker Medical Awards. Inositol trisphosphate, calcium, lithium, and cell signalling. Journal of the American Medical Association, 262, 1834-1841.
13. Bilezikian, J.P. (2000) Primary hyperparathyroidism. When to observe and when to operate. Endocrinology and Metabolism Clinics of North America, 29, 465-478.
14. Bilezikian, J.P., Silverberg, S.J. & Gartenberg, F. (1994) Clinical presentation of primary hyperparathyroidism. In. The Parathyroids (eds J. P. Bilezikian, R. Marcus & M. A. Levine), pp. 457-470. Raven, New York.
15. Bilezikian, J.P., Meng, X., Shi, Y. & Silverberg, S.J. (2000) Primary hyperparathyroidism in women: a tale of two cities: New York and Beijing. International Journal of Fertility and Women's Medicine, 45, 158-165.
16. Bilezikian, J.P., Potts, J.T. Jr, El-Hajij Fuleihan, G., Kleerekoper, M., Neer, R., Peacock, M., Rastad, J., Silverberg, S., Udelsman, R. & Wells Jr, S.A. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Mineral and Bone Metabolism, 17 (Suppl. 2), N2-N11.
17. Boggs, J.E., Irvin, G.L III, Molinari, A.S. & Deriso, G.T. (1996) Intraoperative parathyroid hormone monitoring as an adjunct to parathyroidectomy. Surgery, 120, 954-958.
18. Boucher, A., D'Amour, P., Hamel, L., Fugere, P., Gascon-Barre, M., Lepage, R. & Ste-Marie, L.G. (1989) Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 68, 831-836.
19. Breslau, N.A. (1988) Normal and abnormal regulation of 1,25-(OH) 2D synthesis. American Journal of Medical Sciences, 296, 417-425.
20. Broadus, A.B., Magee, J.S., Mallette, L.E., Horst, R.L., Lang, R., Jensen, P.S., Gertner, J.M. & Baron, R. (1983) A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 56, 953-961.
21. Brochier, T., Adnet-Kessous, J., Barillot, M. & Pascalis, J.G. (1994) Hyperparathyroidism with lithium. Encephale, 20, 339-349.
22. Brown, A.J., Zhong, M., Finch, J., Ritter, C., McCracken, R., Morrissey, J. & Slatopolsky, E. (1996) Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. American Journal of Physiology, 270, F454-F460.
23. Brown, E.M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M.A., Lytton, J. & Hebert, S.C. (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature, 366, 575-580.
24. Brown, E.M., Pollak, M. & Hebert, S.C. (1998) The extracellular calcium-sensing receptor: its role in health and disease. Annual Review of Medicine, 49, 15-29.
25. Bushinsky, D.A. & Krieger, N.S. (1992a) Integration of calcium metabolism in the adult. In: Disorders of Bone and Mineral Metabolism (eds F. L. Coe & M. J. Favus), pp. 417-432. New York: Raven.
26. Bushinsky, D.A. & Krieger, N.S. (1992b) Role of the skeleton in calcium homeostasis. In: The Kidney: Physiology and Pathophysiology (eds D. W. Seldin & G. Giebisch), pp. 2395-2430. New York: Raven.
27. Bushinsky, D.A. & Monk, R.D. (1998) Calcium. Lancet, 352, 306-311.
28. Carling, T., Kindmark, A., Hellman, P., Lundgren, E., Ljunghall, S., Rastad, J., Akerstrom, G. & Melhus, H. (1995) Vitamin D receptor genotypes in primary hyperparathyroidism. Nature Medicine, 12, 1309-1311.
29. Carling, T., Rastad, J., Kindmark, A., Lundgren, E., Ljunghall, S. & Akerstrom, G. (1997) Estrogen receptor polymorphism in postmenopausal primary hyperparathyroidism. Surgery, 122, 1101-1106.
30. Carling, T., Correa, P., Hessman, O., Hedberg, J., Skogseid, B., Lindberg, D., Rastad, J. & Westin, G. (1998) Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 2960-2963.
31. Carling, T., Szabo, E., Bai, M., Ridefelt, P., Westin, G., Gustavsson, P., Trivedi, S., Hellman, P., Brown, E.M., Dahl, N. & Rastad, J. (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. Journal of Clinical Endocrinology and Metabolism, 85, 2042-2047.
32. Carpten, J.D., Robbins, C.M., Villablanca, A., Forsberg, L., Presciuttini, S., Bailey-Wilson, J., Simonds, W.F., Gillanders, E.M., Kennedy, A.M., Chen, J.D., Agarwal, S.K., Sood, R., Jones, M.P., Moses, T.Y., Haven, C., Petillo, D., Leotlela, P.D., Harding, B., Cameron, D., Pannett, A.A., Hoog, A., Heath, H. III, James-Newton, L.A., Robinson, B., Zarbo, R.J., Cavaco, B.M., Wassif, W., Perrier, N.D., Rosen, I.B., Kristofferson, U., Turnpenny, P.D., Farnebo, L.-O., Besser, G.M., Jackson, C.E., Morreau, H., Trent, J.M., Thakker, R.V., Marx, S.J., Teh, B.T., Larsson, C., & Hobbs, M.R. (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genetics, 32, 676-680.
33. Cetani, F., Pinchera, A., Pardi, E., Cianferotti, L., Vignali, E., Picone, A., Miccoli, P., Viacava, P. & Marcocci, C. (1999) No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. Journal of Bone and Mineral Research, 14, 878-882.
34. Chandrasekharappa, S.C., Guru, S.C., Manickam, P., Olufemi, S.E., Collins, F.S., Emmert-Buck, M.R., Debelenko, L.V., Zhuang, Z., Lubensky, I.A., Liotta, L.A., Crabtree, L.S., Wang, Y., Roe, B.A., Weisemann, J., Boguski, M.S., Kester, M.B., Kim, Y.S., Heppner, C., Dong, Q., Spiegel, A.M., Burns, A.L. & Marx, S.J. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science, 276, 404-407.
35. Christensson, T., Hellstrom, K., Wengle, B., Alveryd, A. & Wikland, B. (1976) Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Medica Scandinavica, 200, 131-137.
36. Clark, O.H. (1994) 'Asymptomatic' primary hyperparathyroidism: is parathyroidectomy indicated? Surgery, 116, 947-953.
37. Clemens, T.L., Zhou, X.Y., Myles, M., Endres, D. & Lindsay, R. (1986) Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. Journal of Clinical Endocrinology and Metabolism, 63, 656-660.
38. Cole, D.E.C., Peltekova, V.D., Rubin, L.A., Hawker, G.A., Vieth, R., Liew, C.C., Hwang, D.M., Evrovski, J. & Hendy, G.N. (1999) A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet, 353, 112-115.
39. Corbetta, S., Mantovani, G., Lania, A., Borgato, S., Vicentini, L., Beretta, E., Faglia, G., Di Blasio, A.M. & Spada, A. (2000) Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clinical Endocrinology, 52, 339-348.
40. Correa, P., Rastad, J., Schwarz, P., Westin, G., Kindmark, A., Lundgren, E., Akerstrom, G. & Carling, T. (1999) The vitamin D receptor (VDR) start codon polymorphism in primary hyperparathyroidism and parathyroid VDR messenger ribonucleic acid levels. Journal of Clinical Endocrinology and Metabolism, 84, 1690-1694.
41. Crabtree, J.S., Scacheri, P.C., Ward, J.M., Garrett-Beal, L., Emmert-Buck, M.R., Edgemon, K.A., Lorang, D., Libutti, S.K., Chandrasekharappa, S.C., Marx, S.J., Spiegel, A.M. & Collins, F.S. (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 98, 1118-1123.
42. Cryns, V.L., Yi, S.M., Tahara, H., Gaz, R.D. & Arnold, A. (1995) Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes, Chromosomes and Cancer, 13, 9-17.
43. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.C., Shah, A.S., Huster, W.J., Draper, M. & Christiansen, C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine, 337, 1641-1647.
44. Demay, M.B., Kiernan, M.S., DeLuca, H.F. & Kronenberg, H.M. (1992) Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences of the United States of America, 89, 8097-8101.
45. Dhingra, K. (2001) Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Investigation, 19, 649-659.
46. Diamond, T., Ng, A.T., Levy, S., Magarey, C. & Smart, R. (1996) Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporosis International, 6, 329-333.
47. Dinnen, J.S., Greenwood, R.H., Jones, J.H., Walker, D.A. & Williams, D.E. (1977) Parathyroid carcinoma in familial hyperparathyroidism. Journal of Clinical Pathology, 30, 966-975.
48. Divieti, P., Inomata, N., Chapin, K., Singh, R., Juppner, H. & Bringhurst, F.R. (2001) Receptors for the carboxyl-terminal region of PTH (1-84) are highly expressed in osteocytic cells. Endocrinology, 142, 916-925.
49. Dotzenrath, C., Teh, B.T., Farnebo, F., Cupisti, K., Svensson, A., Toell, A., Goretzki, P. & Larsson, C. (1996) Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? Journal of Clinical Endocrinology and Metabolism, 81, 3194-3196.
50. Douglas, D.L., Kanis, J.A., Paterson, A.D., Beard, D.J., Cameron, E.C., Watson, M.E., Woodhead, S., Williams, J. & Russell, R.G. (1983) Drug treatment of primary hyperparathyroidism: use of clodronate disodium. British Medical Journal (Clinical Research Edition), 286, 587-590.
51. Dwight, T., Twigg, S., Delbridge, L., Wong, F.K., Farnebo, F., Richardson, A.L., Nelson, A., Zedenius, J., Philips, J., Larsson, C., Teh, B.T. & Robinson, B. (2000) Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clinical Endocrinology, 53, 85-92.
52. Ebeling, P.R., Sandgren, M.E., DiMagno, E.P., Lane, A.W., DeLuca, H.F. & Riggs, B.L. (1992) Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. Journal of Clinical Endocrinology and Metabolism, 75, 176-182.
53. Edmondson, J.W. & Li, T.K. (1976) The relationship of serum ionized and total calcium in primary hyperparathyroidism. Journal of Laboratory and Clinical Medicine, 87, 624-629.
54. Ettinger, B., Black, D.M., Mitlak, B.H., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., Christiansen, C., Delmas, P.D., Zanchetta, J.R., Stakkestad, J., Gluer, C.C., Krueger, K., Cohen, F.J., Eckert, S., Ensrud, K.E., Avioli, L.V., Lips, P. & Cummings, S.R. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association, 282, 637-645.
55. Farnebo, F., Enberg, U., Grimelius, L., Backdahl, M., Schalling, M., Larsson, C. & Farnebo, L.O. (1997) Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 82, 3481-3486.
56. Farnebo, F., Teh, B.T., Kytola, S., Svensson, A., Phelan, C., Sandelin, K., Thompson, N.W., Hoog, A., Weber, G., Farnebo, L.O. & Larsson, C. (1998) Alterations of the MEN1 gene in sporadic parathyroid tumors. Journal of Clinical Endocrinology and Metabolism, 83, 2627-2630.
57. Farnebo, F., Kytola, S., Teh, B.T., Dwight, T., Wong, F.K., Hoog, A., Elvius, M., Wassif, W.S., Thompson, N.W., Farnebo, L.O., Sandelin, K. & Larsson, C. (1999) Alternative genetic pathways in parathyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 84, 3775-3780.
58. Fiorica, V. & Males, J.L. (1979) Hyperparathyroidism after radiation of the head and neck: a case report and review of the literature. American Journal of the Medical Sciences, 278, 223-228.
59. Forster, J., Monchik, J.M. & Martin, H.F. (1988) A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery, 104, 1137-1142.
60. Frayha, R.A., Nassar, V.H., Dagher, F. & Salti, I.S. (1972) Familial parathyroid carcinoma. Leban Medical Journal, 25, 299-309.
61. Friedman, E., Bale, A.E., Marx, S.J., Norton, J.A., Arnold, A., Tu, T., Aurbach, G.D. & Spiegel, A.M. (1990) Genetic abnormalities in sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism, 71, 293-297.
62. Gao, P., Scheibel, S., D'Amour, P., John, M.R., Rao, S.D., Schmidt-Gayk, H. & Cantor, T.L. (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. Journal of Bone and Mineral Research, 16, 605-614.
63. Glendenning, P., Gutteridge, D.H., Retallack, R.W., Stuckey, B.G., Kermode, D.G. & Kent, G.N. (1998) High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Australian and New Zealand Journal of Medicine, 28, 173-178.
64. Gogusev, J., Duchambon, P., Hory, B., Giovannini, M., Goureau, Y., Sarfati, E. & Drueke, T.B. (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney International, 51, 328-336.
65. Goodman, W.G., Frazao, J.M., Goodkin, D.A., Turner, S.A., Liu, W. & Coburn, J.W. (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney International, 58, 436-445.
66. Grey, A.B., Stapleton, J.P., Evans, M.C., Tatnell, M.A. & Reid, I.R. (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Annals of International Medicine, 125, 360-368.
67. Guo, C.Y., Thomas, W.E., al Dehaimi, A.W., Assiri, A.M. & Eastell, R. (1996) Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 81, 3487-3491.
68. Guru, S.C., Goldsmith, P.K., Burns, A.L., Marx, S.J., Spiegel, A.M., Collins, F.S. & Chandrasekharappa, S.C. (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proceedings of the National Academy of Sciences of the United States of America, 95, 1630-1634.
69. Haden, S.T., Stoll, A.L., McCormick, S., Scott, J. & Fuleihan, G. (1997) Alterations in parathyroid dynamics in lithium-treated subjects. Journal of Clinical Endocrinology and Metabolism, 82, 2844-2848.
70. Hamdy, N.A., Gray, R.E., McCloskey, E., Galloway, J., Rattenbury, J.M., Brown, C.B. & Kanis, J.A. (1987) Clodronate in the medical management of hyperparathyroidism. Bone, 8 (Suppl. 1), S69-S77.
71. Harrison, B.J. & Wheeler, M.H. (1991) Asymptomatic primary hyperparathyroidism. World Journal of Surgery, 15, 724-729.
72. Hasse, C., Sitter, H., Bachmann, S., Zielke, A., Koller, M., Nies, C., Lorenz, W. & Rothmund, M. (2000) How asymptomatic is asymptomatic primary hyperparathyroidism? Experimental and Clinical Endocrinology and Diabetes, 108, 265-274.
73. Heppner, C., Kester, M.B., Debelenko, L.V., Emmert-Buck, M.R., Guru, S.C., Manickam, P., Olufemi, S.E., Skarulis, M.C., Doppman, J.L., Alexander, R.H., Kim, Y.S., Saggar, S.K., Lubensky, I.A., Zhuang, Z., Liotta, L.A., Chandrasekharappa, S.C., Spiegel, A.M., Burns, A.L. & Marx, S.J. (1997) Somatic mutation of the MEN1 gene in parathyroid tumours. Nature Genetics, 16, 375-378.
74. Heppner, C., Bilimoria, K.Y., Agarwal, S.K., Kester, M., Whitty, L.J., Guru, S.C., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M., Marx, S.J. & Burns, A.L. (2001) The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene, 20, 4917-4925.
75. Ho, C., Conner, D.A., Pollak, M.R., Ladd, D.J., Kifor, O., Warren, H.B., Brown, E.M., Seidman, J.G. & Seidman, C.E. (1995) A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nature Genetics, 11, 389-394.
76. Hobson, E.E. & Ralston, S.H. (2001) Role of genetic factors in the pathophysiology and management of osteoporosis. Clinical Endocrinology, 54, 1-9.
77. Horiuchi, T., Onouchi, T., Inoue, J., Shionoiri, A., Hosoi, T. & Orimo, H. (2002) A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology, 48, 103-108.
78. Horowitz, M., Wishart, J., Need, A.G., Morris, H., Philcox, J. & Nordin, B.E. (1987) Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. Archives of International Medicine, 147, 681-685.
79. Hosokawa, Y., Pollak, M.R., Brown, E.M. & Arnold, A. (1995) Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. Journal of Clinical Endocrinology and Metabolism, 80, 3107-3110.
80. Howe, J.R., Norton, J.A. & Wells, S.A.J. (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery, 114, 1070-1077.
81. Hsi, E.D., Zukerberg, L.R., Yang, W.-I. & Arnold, A. (1996) Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism, 81, 1736-1739.
82. Huang, Q.L., Feig, D.S. & Blackstein, M.E. (2000) Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. Journal of Endocrinological Investigation, 23, 263-267.
83. Imanishi, Y., Hosokawa, Y., Yoshimoto, K., Schipani, E., Mallya, S., Papanikolaou, A., Kifor, O., Tokura, T., Sablosky, M., Ledgard, F., Gronowicz, G., Wang, T.C., Schmidt, E.V., Hall, C., Brown, E.M., Bronson, R. & Arnold, A. (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. Journal of Clinical Investigation, 107, 1093-1102.
84. Inagaki, C., Dousseau, M., Pacher, N., Sarfati, E., Drueke, T.B. & Gogusev, J. (1998) Structural analysis of gene marker loci on chromosomes 10 and 11 in primary and secondary uraemic hyperparathyroidism. Nephrology, Dialysis and Transplantation, 13, 350-357.
85. Inomata, N., Akiyama, M., Kubota, N. & Juppner, H. (1995) Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology, 136, 4732-4740.
86. Ishimi, Y., Russell, J. & Sherwood, L.M. (1990) Regulation by calcium and 1,25-(OH) 2D3 of cell proliferation and function of bovine parathyroid cells in culture. Journal of Bone and Mineral Research, 5, 755-760.
87. Jackson, C.E., Norum, R.A., Boyd, S.B., Talpos, G.B., Wilson, S.D., Taggart, R.T. & Mallette, L.E. (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery, 108, 1006-1012.
88. Jorde, R., Bonaa, K.H. & Sundsfjord, J. (2000) Primary hyperparathyroidism detected in a health screening. The Tromso study. Journal of Clinical Epidemiology, 53, 1164-1169.
89. Kaji, H., Sugimoto, T., Kanatani, M., Miyauchi, A., Kimura, T., Sakakibara, S., Fukase, M. & Chihara, K. (1994) Carboxyl-terminal parathyroid hormone fragments stimulate osteoclast-like cell formation and osteoclastic activity. Endocrinology, 134, 1897-1904.
90. Kaji, H., Canaff, L., Lebrun, J.J., Goltzman, D. & Hendy, G.N. (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signalling. Proceedings of the National Academy of Sciences of the United States of America, 98, 3837-3842.
91. Kakinuma, A., Morimoto, I., Nakano, Y., Fujimoto, R., Ishida, O., Okada, Y., Inokuchi, N., Fujihira, T. & Eto, S. (1994) Familial primary hyperparathyroidism complicated with Wilms' tumor. International Medicine, 33, 123-126.
92. 2+-sensing receptor expression in parathyroid adenoma. Calcified Tissue International, 64, 271-272.
93. Kantorovich, V., Gacad, M.A., Seeger, L.L. & Adams, J.S. (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 3541-3543.
94. Kanzawa, M., Sugimoto, T., Kobayashi, A. & Chihara, K. (1999) Parathyroid hormone gene polymorphisms in primary hyperparathyroidism. Clinical Endocrinology, 50, 583-588.
95. Kaun, M., Frilling, A., Plaschke, J., Saeger, H.-D., Broelsch, C.E. & Schackert, H.K. (1997) Vitamin D receptor genotypes in patients with primary and secondary hyperparathyroidism. Langenbeck's Archiv der Chirurgie Forumband, 1997, 773-775.
96. Khosla, S., Ebeling, P.R., Firek, A.F., Burritt, M.M., Kao, P.C. & Heath, H. (1993) Calcium infusion suggests a 'set-point' abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 76, 715-720.
97. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 81, 1598-1606.
98. Kifor, O., MacLeod, R.J., Diaz, R., Bai, M., Yamaguchi, T., Yao, T., Kifor, I. & Brown, E.M. (2001) Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. American Journal of Physiology, 280, F291-F302.
99. Knudson Jr, A.G. (1971) Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68, 820-823.
100. Knudson Jr, A.G. (1977) Mutation and cancer in man. Cancer, 39 (4 Suppl.), 1882-1886.
101. Kobayashi, T., Sugimoto, T., Kobayashi, A. & Chihara, K. (1998) Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. Endocrine Journal of, 45, 123-125.
102. Kotzmann, H., Svoboda, T., Bernecker, P., Clodi, M., Woloszczuk, W., Niederle, B., Waldhausl, W. & Luger, A. (1994) Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism. Wiener Klinischewochenschrift, 106, 422-425.
103. Kremer, R., Bolivar, I., Goltzman, D. & Hendy, G.N. (1989) Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology, 125, 935-941.
104. Kristiansen, J.H., Rodbro, P., Christiansen, C., Brochner, M.J. & Carl, J. (1985) Familial hypocalciuric hypercalcaemia. II. Intestinal calcium absorption and vitamin D metabolism. Clinical Endocrinology, 23, 511-515.
105. Kristensen, B., Mouridsen, H.T., Holmegaard, S.N. & Transbol, I. (1989) Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer. Cancer, 64, 1965-1967.
106. Krubsack, A.J., Wilson, S.D., Lawson, T.L., Kneeland, J.B.,Thorsen, M.K., Collier, B.D., Hellman, R.S. & Isitman, A.T. (1989) Prospective comparison of radionuclide, computed tomographic, sonographic, and magnetic resonance localization of parathyroid tumors. Surgery, 106, 639-644.
107. Kumar, R. (1984) Metabolism of 1,25-dihydroxyvitamin D3. Physiological Review, 64, 478-504.
108. Kytola, S., Farnebo, F., Obara, T., Isola, J., Grimelius, L., Farnebo, L.O., Sandelin, K. & Larsson, C. (2000) Patterns of chromosomal imbalances in parathyroid carcinomas. American Journal of Pathology, 157, 579-586.
109. Lander, E.S. & Schork, N.J. (1994) Genetic dissection of complex traits. Science, 265, 2037-2048.
110. LeBoff, M.S., Rennke, H.G. & Brown, E.M. (1983) Abnormal regulation of parathyroid cell secretion and proliferation in primary cultures of bovine parathyroid cells. Endocrinology, 113, 277-284.
111. Leborgne, J., Le Neel, J.-C., Buzelin, F. & Malvy, P. (1975) Cancer familial des parathyroides: interet de l'angiographie dans le diagnostic des recidives locoregionales-considerations a propos de deux cas. Journal of Chirurgie Paris, 109, 315-326.
112. Lemmens, I.H., Forsberg, L., Pannett, A.A., Meyen, E., Piehl, F., Turner, J.J., Van de Ven, W.J., Thakker, R.V., Larsson, C. & Kas, K. (2001) Menin interacts directly with the homeobox-containing protein Pem. Biochemical and Biophysical Research Communications, 286, 426-431.
113. LoCascio, V., Braga, V., Bertoldo, F., Bettica, P., Pasini, A.F., Stefani, L. & Moro, L. (1994) Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. Clinical Endocrinology, 41, 47-51.
114. Lorenz, K., Miccoli, P., Monchik, J.M., Duren, M. & Dralle, H. (2001) Minimally invasive video-assisted parathyroidectomy: multiinstitutional study. World Journal of Surgery, 25, 704-707.
115. Lundgren, E., Ljunghall, S., Akerstrom, G., Hetta, J., Mallmin, H. & Rastad, J. (1998) Case-control study on symptoms and signs of 'asymptomatic' primary hyperparathyroidism. Surgery, 124, 980-985.
116. McDermott, M.T., Perloff, J.J. & Kidd, G.S. (1994) Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. Journal of Bone and Mineral Research, 9, 509-514.
117. McHenry, C.R., Racke, F., Meister, M., Warnaka, P., Sarasua, M., Nemeth, E.F. & Malangoni, M.A. (1991) Lithium effects on dispersed bovine parathyroid cells grown in tissue culture. Surgery, 110, 1061-1066.
118. McHenry, C.R., Stenger, D.B. & Racke, F. (1995) Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells. American Journal of Surgery, 170, 484-487.
119. McKane, W.R., Khosla, S., Egan, K.S., Robins, S.P., Burritt, M.F. & Riggs, B.L. (1996) Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. Journal of Clinical Endocrinology and Metabolism, 81, 1699-1703.
120. McLeod, M.K., Monchik, J.M. & Martin, H.F. (1984) The role of ionized calcium in the diagnosis of subtle hypercalcemia in symptomatic primary hyperparathyroidism. Surgery, 95, 667-673.
121. Mallya, S.M. & Arnold, A. (2000) Cyclin D1 in parathyroid disease. Frontiers in Bioscience, 5, D367-D371.
122. Mandell, D.L., Genden, E.M., Mechanick, J.I., Bergman, D.A., Diamond, E.J. & Urken, M.L. (2001) The influence of intraoperative parathyroid hormone monitoring on the surgical management of hyperparathyroidism. Archives of Otolaryngology - Head Neck Surgery, 127, 821-827.
123. Marx, S.J. (2000) Hyperparathyroid and hypoparathyroid disorders. New England Journal of Medicine, 343, 1863-1875.
124. Marx, S.J., Attie, M.F., Levine, M.A., Spiegel, A.M., Downs, R.W. Jr & Lasker, R.D. (1981) The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine, 60, 397-412.
125. Miccoli, P. (2002) Minimally invasive surgery for thyroid and parathyroid diseases. Surgical Endoscopy, 16, 3-6.
126. Miedlich, S., Krohn, K., Lamesch, P., Muller, A. & Paschke, R. (2000) Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism. European Journal of Endocrinology, 143, 47-54.
127. Miedlich, S., Lamesch, P., Mueller, A. & Paschke, R. (2001a) Frequency of the calcium-sensing receptor variant A986S in patients with primary hyperparathyroidism. European Journal of Endocrinology, 145, 421-427.
128. Miedlich, S., Lohmann, T., Schneyer, U., Lamesch, P. & Paschke, R. (2001b) Familial isolated primary hyperparathyroidism: a multiple endocrine neoplasia type 1 variant? European Journal of Endocrinology, 145, 155-160.
129. Moltz, K.C., Friedman, A.H., Nehgme, R.A., Kleinman, C.S. & Carpenter, T.O. (2001) Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Current Opinion in Pediatrics, 13, 373-375.
130. Mork, A. (1993) Actions of lithium on the cyclic AMP signalling system in various regions of the brain: possible relations to its psychotropic actions. A study on the adenylate cyclase in rat cerebral cortex, corpus striatum and hippocampus. Pharmacology and Toxicology, 73 (Suppl. 3), 1-47.
131. Morrison, N.A., Qi, J.C., Tokita, A., Kelly, P.J., Crofts, L., Nguyen, T.V., Sambrook, P.N. & Eisman, J.A. (1994) Prediction of bone density from vitamin D receptor alleles. [published erratum appears in Nature 1997, 387 (6628), 106]. Nature, 367, 284-287.
132. Motokura, T., Bloom, T., Kim, H.G., Juppner, H., Ruderman, J.V., Kronenberg, H.M. & Arnold, A. (1991) A novel cyclin encoded by a bc11-linked candidate oncogene. Nature, 350, 512-515.
133. Mourad, M., Ngongang, C., Saab, N., Coche, E., Jamar, F., Michel, J.M., Maiter, D., Malaise, J. & Squifflet, J.P. (2001) Video-assisted neck exploration for primary and secondary hyperparathyroidism: initial experience. Surgical Endoscopy, 15, 1112-1115.
134. Murray, T.M., Rao, L.G. & Muzaffar, S.A. (1991) Dexamethasone- treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): stimulation of alkaline phosphatase. Calcified Tissue International, 49, 120-123.
135. Nakanishi, S., Kazama, J.J., Shigematsu, T., Iwasaki, Y., Cantor, T.L., Kurosawa, T. & Fukagawa, M. (2001) Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. American Journal of Kidney Diseases, 38, S172-S174.
136. Naveh-Many, T., Friedlaender, M.M., Mayer, H. & Silver, J. (1989) Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat: dominant role of 1,25-dihydroxyvitamin D. Endocrinology, 125, 275-280.
137. Naveh-Many, T., Rahamimov, R., Livni, N. & Silver, J. (1995) Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. Journal of Clinical Investigation, 96, 1786-1793.
138. Nemeth, E.F., Steffey, M.E., Hammerland, L.G., Hung, B.C., Van Wagenen, B.C.I., Mar, E.G. & Balandrin, M.F. (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proceedings of the National Academy of Sciences of the United States of America, 95, 4040-4045.
139. Nguyen-Yamamoto, L., Rousseau, L., Brossard, J.H., Lepage, R. & D'Amour, P. (2001) Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology, 142, 1386-1392.
140. Nygren, P., Larsson, R., Johansson, H., Ljunghall, S., Rastad, J. & Akerstrom, G. (1988) 1,25 (OH) 2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcified Tissue International, 43, 213-218.
141. O'Regan, R.M. & Gradishar, W.J. (2001) Selective estrogen-receptor modulators in 2001. Oncology 15, 1177-1190.
142. Ohkura, N., Kishi, M., Tsukada, T. & Yamaguchi, K. (2001) Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochemical and Biophysical Research Communications, 282, 1206-1210.
143. Orr-Walker, B.J., Evans, M.C., Clearwater, J.M., Horne, A., Grey, A.B. & Reid, I.R. (2000) Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: 4-year follow-up and comparison with healthy postmenopausal women. Archives of International Medicine, 160, 2161-2166.
144. Pacheco, D., Menarguez, J., Cristobal, E., Arribas, B., Alcazar, J.A., Carrion, R. & Polo, J.R. (2000) BsmI vitamin D receptor polymorphism and pathogenesis of parathyroid adenoma. Medical Science Monitor, 6, 658-660.
145. Palanisamy, N., Imanishi, Y., Rao, P.H., Chaganti, R.S.K. & Arnold, A. (1998) Novel chromosomal abnormalities identified by comparative genomic hybridisation in parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism, 83, 1766-1770.
146. Palmer, M., Ljunghall, S., Akerstrom, G., Adami, H.O., Bergstrom, R., Grimelius, L., Rudberg, C. & Johansson, H. (1987) Patients with primary hyperparathyroidism operated on over a 24-year period: temporal trends of clinical and laboratory findings. Journal of Chronic Diseases, 40, 121-130.
147. Palmer, M., Jakobsson, S., Akerstrom, G. & Ljunghall, S. (1988) Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. European Journal of Clinical Investigation, 18, 39-46.
148. Pearce, S.H., Trump, D., Wooding, C., Sheppard, M.N., Clayton, R.N. & Thakker, R.V. (1996) Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clinical Endocrinology (Oxford), 45, 195-200.
149. Prince, R.L., Schiff, I. & Neer, R.M. (1990) Effects of transdermal estrogen replacement on parathyroid hormone secretion. Journal of Clinical Endocrinology and Metabolism, 71, 1284-1287.
150. Prince, R.L., MacLaughlin, D.T., Gaz, R.D. & Neer, R.M. (1991) Lack of evidence for estrogen receptors inhuman and bovine parathyroid tissue. Journal of Clinical Endocrinology and Metabolism, 72, 1226-1228.
151. Racke, F., McHenry, C.R. & Wentworth, D. (1994) Lithium-induced alterations in parathyroid cell function: insight into the pathogenesis of lithium-associated hyperparathyroidism. American Journal of Surgery, 168, 462-465.
152. Rao, D.S., Honasoge, M., Divine, G.W., Phillips, E.R., Lee, M.W., Ansari, M.R., Talpos, G.B. & Parfitt, A.M. (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. Journal of Clinical Endocrinology and Metabolism, 85, 1054-1058.
153. Reasner, C.A., Stone, M.D., Hosking, D.J., Ballah, A. & Mundy, G.R. (1993) Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. Journal of Clinical Endocrinology and Metabolism, 77, 1067-1071.
154. Rossini, M., Gatti, D., Isaia, G., Sartori, L., Braga, V. & Adami, S. (2001) Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone and Mineral Research, 16, 113-119.
155. Roussanne, M.C., Lieberherr, M., Souberbielle, J.C., Sarfati, E., Drueke, T. & Bourdeau, A. (2001) Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. European Journal of Clinical Investigation, 31, 610-616.
156. Russ, J.E., Scanlon, E.F. & Sener, S.F. (1979) Parathyroid adenomas following irradiation. Cancer, 43, 1078-1083.
157. Russell, J., Lettieri, D. & Sherwood, L.M. (1983) Direct regulation by calcium of cytoplasmic messenger ribonucleic acid coding for preproparathyroid hormone in isolated bovine parathyroid cells. Journal of Clinical Investigation, 72, 1851-1855.
158. Salata, R. & Klein, I. (1987) Effects of lithium on the endocrine system: a review. Journal of Laboratory and Clinical Medicine, 110, 130-136.
159. Sandelin, K., Skoog, L., Humla, S. & Farnebo, L.O. (1992) Oestrogen, progesterone, and glucocorticoid receptors in normal and neoplastic parathyroid glands. European Journal of Surgery, 158, 467-472.
160. Selby, P.L. & Peacock, M. (1986) Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. New England Journal of Medicine, 314, 1481-1485.
161. Shan, L., Nakamura, M., Nakamura, Y., Inoue, D., Morimoto, S., Yokoi, T. & Kakudo, K. (1997) Comparative analysis of clonality and pathology in primary and secondary hyperparathyroidism. Virchows Archiv, 430, 247-251.
162. Shoback, D.M., Bilezikian, J., Binder, T.A., Graves, T., Turner, S.A. & Peacock, M. (2000) AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism. Journal of Bone and Mineral Research, 15 (Suppl. 1), S210.
163. Shoback, D.M., Firek, A.F., Mims, R.B., Binder, T.A., Graves, T., Turner, S.A. & Peacock, M. (2001) An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism. Journal of Bone and Mineral Research, 16 (Suppl. 1), S303.
164. Silverberg, S.J. & Bilezikian, J.P. (1997) Primary hyperparathyroidism: still evolving? Journal of Bone and Mineral Research, 12, 856-862.
165. Silverberg, S.J., Bone, H.G., Marriott, T.B., Locker, F.G., Thys-Jacobs, S., Dziem, G., Kaatz, S., Sanguinetti, E.L. & Bilezikian, J.P. (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. New England Journal of Medicine, 337, 1506-1510.
166. Silverberg, S.J., Shane, E., Dempster, D.W. & Bilezikian, J.P. (1999a) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine, 107, 561-567.
167. Silverberg, S.J., Shane, E., Jacobs, T.P., Siris, E. & Bilezikian, J.P. (1999b) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. [published erratum appears in New England Journal of Medicine 2000, 342, 144]. New England Journal of Medicine, 341, 1249-1255.
168. Simonds, W.F., James-Newton, L.A., Agarwal, S.K., Yang, B., Skarulis, M.C., Hendy, G.N. & Marx, S.J. (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine, 81, 1-26.
169. Sosa, M., Torres, A., Martin, N., Salido, E., Liminana, J.M., Barrios, Y., De Miguel, E. & Betancor, P. (2000) The distribution of two different vitamin D receptor polymorphisms (BsmI and start codon) in primary hyperparathyroidism. Journal of International Medicine, 247, 124-130.
170. Streeten, E.A., Weinstein, L.S., Norton, J.A., Mulvihill, J.J., White, B.J., Friedman, E., Jaffe, G., Brandi, M.L., Stewart, K. & Zimering, M.B. (1992) Studies in a kindred with parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 75, 362-366.
171. Strewler, G.J. (1995) Indications for surgery in patients with minimally symptomatic primary hyperparathyroidism. Surgical Clinics of North America, 75, 439-447.
172. Tahara, H., Smith, A.P., Gaz, R.D. & Arnold, A. (1996) Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism, 81, 3663-3667.
173. Teh, B.T., Farnebo, F., Kristoffersson, U., Sundelin, B., Cardinal, J., Axelson, R., Yap, A., Epstein, M., Heath, H., Cameron, D. & Larsson, C. (1996) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. Journal of Clinical Endocrinology and Metabolism, 81, 4204-4211.
174. Teh, B.T., Farnebo, F., Twigg, S., Hoog, A., Kytola, S., Korpi-Hyovalti, E., Wong, F.K., Nordenstrom, J., Grimelius, L., Sandelin, K., Robinson, B., Farnebo, L.O. & Larsson, C. (1998) Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. Journal of Clinical Endocrinology and Metabolism, 83, 2114-2120.
175. Thakker, R.V. (1998) Multiple endocrine neoplasia syndromes of the 20th century. Journal of Clinical Endocrinology and Metabolism, 83, 2617-2620.
176. Tominaga, Y., Tsuzuki, T., Uchida, K., Haba, T., Otsuka, S., Ichimori, T., Yamada, K., Numano, M., Tanaka, Y. & Takagi, H. (1999) Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney International, 55, 1375-1383.
177. Tritsaris, K., Gromada, J., Jorgensen, T.D., Nauntofte, B. & Dissing, S. (2001) Reduction in the rate of inositol 1,4,5-trisphosphate synthesis in rat parotid acini by lithium. Archives of Oral Biology, 46, 365-373.
178. Trump, D., Farren, B., Wooding, C., Pang, J.T., Besser, G.M., Buchanan, K.D., Edwards, C.R., Heath, D.A., Jackson, C.E., Jansen, S., Lips, K., Monson, J.P., O'Halloran, D., Sampson, J., Shalet, S.M., Wheeler, M.H., Zink, A. & Thakker, R.V. (1996) Clinical studies of multple endocrine neoplasia type 1 (MEN1). Quarterly Journal of Medicine, 89, 653-669.
179. Tsukamoto, Y., Moriya, R., Nagaba, Y., Morishita, T., Izumida, I. & Okubo, M. (1995) Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. American Journal of Kidney Diseases, 25, 879-886.
180. Wada, M., Furuya, Y., Sakiyama, J., Kobayashi, N., Miyata, S., Ishii, H. & Nagano, N. (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. Journal of Clinical Investigation, 100, 2977-2983.
181. Wada, M., Nagano, N., Furuya, Y., Chin, J., Nemeth, E.F. & Fox, J. (2000) Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney International, 57, 50-58.
182. Wasnich, R.D. & Miller, P.D. (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. Journal of Clinical Endocrinology and Metabolism, 85, 231-236.
183. Wermers, R.A., Khosla, S., Atkinson, E.J., Hodgson, S.F., O'Fallon, W.M. & Melton, L.J. (1997) The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Annals of International Medicine, 126, 433-440.
184. Wolf, M.E., Moffat, M., Mosnaim, J. & Dempsey, S. (1997) Lithium therapy, hypercalcemia, and hyperparathyroidism. American Journal of Therapeutics, 4, 323-325.
185. Wu, C.J., Song, Y.M. & Sheu, W.H. (2000) Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. International Medicine, 39, 468-471.
186. Yano, S., Sugimoto, T., Tsukamoto, T., Chihara, K., Kobayashi, A., Kitazawa, S., Maeda, S. & Kitazawa, R. (2000) Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney International, 58, 1980-86.
187. Younis, E., Jarrah, N., Sroujieh, A.S., Al Hadidy, A. & Ajlouni, K. (2001) Tertiary hyperparathyroidism after high-dose phosphate therapy in adult-onset hypophosphatemic osteomalacia. Endocrine Practice, 7, 375-378.
188. Zanchetta, J.R. & Bogado, C.E. (2001) Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. Journal of Bone and Mineral Research, 16, 189-190.
189. Zofkova, I., Rojdmark, S. & Kancheva, R.L. (1993) Does estrogen replacement therapy influence parathyroid hormone responsiveness to exogenous hypercalcemia in postmenopausal women? Journal of Endocrinological Investigation, 16, 323-327.